Price
No data yet.
Social Signal Score
Revenue
$81.0K-92.51%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Johan Spoor
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 165
- Beta
- 1.80
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.46
Financials
Revenue
$81.0K-92.5%Net Income
$-26.79MEBITDA
$-26.72MFree Cash Flow
$-34.84MEPS (diluted)
$-0.36Shares Outstanding (diluted)
73.81M+34.2%Operating Expenses
$29.34MCash & Debt
$236.88MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-103.12M | $-1.40 |
| 2024 | $1.45M | $-79.28M | $-1.23 |
| 2023 | $1.43M | $-46.51M | $-0.85 |
| 2022 | $5.42M | $-10.76M | $-0.60 |
| 2021 | $10.79M | $-7.27M | $-0.50 |
| 2020 | $10.05M | $-3.19M | $-0.06 |
| 2019 | $9.68M | $-3.27M | $-0.05 |
| 2018 | $7.31M | $-4.85M | $-0.07 |
| 2017 | $5.92M | $-6.70M | $-0.12 |
| 2016 | $4.76M | $-6.16M | $-0.11 |
| 2015 | $4.77M | $-4.71M | $-0.09 |
| 2014 | $4.61M | $-3.68M | $-0.07 |
| 2013 | $4.22M | $-5.96M | $-0.14 |
| 2012 | $4.53M | $-3.86M | $-0.11 |
Valuation
CATXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for SSTR2-expressing NETs shows sustained efficacy and safety, with pivotal Phase 3 initiation targeted for late 2026. Upcoming data readouts for both NET and MC1R-positive melanoma programs, including ESMO 20
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-0.25 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.22 vs $-0.25beat
- Mon, May 11$-0.25 vs $-0.29beat
- Mon, Mar 16$-0.51 vs $-0.37miss
- Mon, Nov 10$-0.35 vs $-0.33miss
- Wed, Aug 13$-0.30 vs $-0.30beat
- Mon, May 12$-0.25 vs $-0.28beat
Estimates and results for CATX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CATX officers and directors.
- Bought
- $58.8m
- Sold
- —
45 trades
0 trades
- Hunt Jonathan Robertbought
- Williamson Robert F Iiibought
- Williamson Robert F Iiibought
- Woods Lori Abought
- Spoor Johan M.bought
- Spoor Johan M.bought
- Williamson Robert F Iiibought
- Graham Juanbought
35 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.